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SUMMARY  Body dysmorphic disorder is a relatively common yet long 
unrecognized problem affecting mainly adolescents and young adults of 
both sexes. It is an obsessive disease of such intensity that it interferes 
with daily activities. Patients typically focus on imagined major defects 
in the face, nose, skin or hair. Patients often seek multiple physician 
assessment, but body dysmorphic disorder may be disabling and even 
life-threatening as a result of depression and suicidal ideation. Treatment 
with serotonin reuptake inhibitors and cognitive behavioral therapy may 
be beneficial in many patients.
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 INTRODUCTION
 Long unrecognized, body dysmorphic disor-
der (BDD) is a relatively common problem affect-
ing mainly adolescents and young adults of both 
sexes. It manifests as an unreasonable obsession 
with the appearance of any part of the body with 
such intensity that it interferes with daily activities. 
The face, nose, skin and hair are the most com-
mon areas of concern. As a result, patients often 
seek treatment from dermatologists and plastic 
surgeons in their search for an imaginary cure, 
which often remains unfulfilled. It is important 
that they be identified and referred to health care 
specialists, as this disorder may be disabling and 
even life-threatening, leading to depression and an 
increased rate of suicide if untreated (1,2). Treat-
ment with selective serotonin reuptake inhibitors 
(SSRIs) and cognitive behavioral therapy (CBT) 
has been demonstrated to be successful in many 
cases.
 DEFINITION
 First classified as dysmorphophobia within 
atypical somatoform disorders, BDD was not for-
mally labeled as such until 1987 in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-
III-R), and criteria were only recently clarified in 
DSM-IV in 1994 (3). It is defined as an obsessive 
and irrational preoccupation with a slight or imagi-
nary defect in one’s physical appearance, to such 
a degree that it interferes with social, occupational 
or other activities. It is often associated with other 
conditions such as social anxiety, depressive, ob-
sessive-compulsive and eating disorders (4,5). 
Delusions may be present in the more severe sub-
types. It is mandatory to exclude any other mental 
disorder that could explain the preoccupation.
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 PREVALENCE
 Underdiagnosed and under-recognized for 
years, BDD affects 1% to 2% of the US popula-
tion, involving both sexes, with an onset usually 
before the age of 18 (6,7). In a comparative survey 
of German and American college students, 5.3% 
and 4% of participants, respectively, satisfied the 
criteria for BDD. Poor body image significantly cor-
related to poor self-esteem, anxiety, depression, 
and obsessive-compulsive symptoms (8,9). It is 
overly represented in some groups. Up to 10% of 
patients with anxiety or depressive disorders are 
affected (10). Many patients will seek a cosmetic 
or surgical procedure to improve their perceived 
defect. Phillips et al. (11) found a prevalence of 
10% to 14% in a screening of such clinics. 
 PATHOPHYSIOLOGY
 Research supports a disturbance in serotonin 
activity which may also be found in obsessive-
compulsive disorders as well as eating disorders 
such as anorexia nervosa and bulimia.
 CLINICAL PRESENTATION
 Teenagers tend to be self-conscious of their 
appearance, but in individuals with BDD, slight de-
fect in a body part is blown out of proportion and 
becomes an obsession, causing significant dis-
tress, leading to time-consuming compulsive be-
haviors and interfering with daily activities. Many 
are reluctant to admit their concerns, as insight is 
often poor and some are delusional. They tend to 
be shy and overly absorbed with the area of con-
cern. Nearly all patients suffer some impairment in 
functioning as a result of their symptoms, some to 
a debilitating degree, which can lead to repeated 
hospitalizations, depression and suicide (12). A 
nonexistent or slight flaw of the face is often the 
primary complaint. In a study of children and ado-
lescents, Albertini and Phillips (13) showed that the 
skin and the hair were the main areas of focus in 
61% and 55%, respectively. The slightest blemish, 
whether freckles or a mole, mild acne, minor scars 
or wrinkles induce disproportionate anxiety and 
disruption in their self-esteem, which may bring 
them to seek care of a dermatologist, cosmetic 
or plastic surgeon (14). The hair is also a major 
area of concern, from too little on the head to too 
much on the face and body, as well as the shape 
and size of the nose, face or any other body part, 
breast, genitalia as well muscle mass in boys. In 
boys and men, it may be expressed as an obses-
sion to build muscles and may lead to the intake 
of anabolic steroids (15). In dermatology practice, 
it may manifest as a preoccupation with acne and 
excoriated acne or skin picking (16). About one 
third of patients report compulsive skin picking for 
hours a day, at times with tweezers, pins, needles 
or even razor blades, causing considerable dam-
age at times. Some are unwilling to describe the 
perceived deformity and will only refer to their “ug-
liness”. 
 Comparing themselves to others, they become 
convinced that the defect is immediately obvious 
not only to themselves but to anybody who looks 
at them, even though it is barely or not notice-
able. They spend a considerable amount of time 
compulsively trying to hide the perceived defect 
with make-up, clothing, or hair styling, comparing 
it to others, checking in the mirror or avoiding mir-
rors. BDD has been shown to highly correlate with 
lower self-esteem, obsessive-compulsive activi-
ties, depression and somatization (17). If unrecog-
nized by practitioners, patients may go from one 
cosmetic surgery or procedure to another, in their 
frustrated search for unattainable results. In one 
study, dermatologic, dental or surgical procedures 
had been sought and performed in 36% of cases, 
all with a poor outcome (12). Most patients suf-
fer impairment in their social life, job or academic 
career. BDD induces marked distress and anxiety, 
and may lead to social phobia and isolation from 
fear of negative evaluation, obsessive-compulsive 
behaviors, delusions and intrusive thoughts about 
one’s ugliness, depression, suicide and repeated 
psychiatric hospitalizations (18,19). Comorbidi-
ties such as marked social phobia, depression 
and links to eating disorders are often present. In 
adults with BDD, major depression is present in 
60% of cases and 80% have a history of depres-
sion (20,21). It has been shown that BDD may pre-
cede anorexia nervosa in up to 25% of patients, 
but it is important to differentiate the two, even if 
both are associated (22-24). 
  ETIOLOGY 
 The cause of BDD is unknown (25,26), but 
genetics as well as a number of factors may pre-
cipitate its onset in predisposed individuals. Ge-
netic factors are believed to play a role. Although 
no specific gene has been found, a predisposition 
to anxiety, perfectionism and obsessive-compul-
sive behaviors has been noted in some families.
People with BDD tend to have unrealistic expec-
tations of themselves and others. They may lack 
the sense of identity and become angry or  even
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violent at times, in particular with physicians caring 
for them, as their search for a solution goes unful-
filled (14). A destabilizing event such as puberty, 
family problems, or a new environment may be a 
trigger. Some may suffer from overprotective fami-
lies, while others may feel abandoned, lonely, and 
misunderstood. At some point, pressure may have 
come from friends or peers. Some may feel insecure, 
isolated, with few or no friend for fear of rejection. 
 The media may also contribute to this percep-
tion by continuously projecting images of happi-
ness and success associated with supposedly 
perfect faces and bodies of tightly screened mod-
els.
 DIAGNOSIS 
 BDD often goes unrecognized and undiag-
nosed as patients try their best to keep their con-
cerns undiscovered from shame and embarras- 
sment as well as from the lack of insight (26-28). 
Primary complaints may be misleading both to 
mental health providers and dermatologic or cos-
metic surgeons (29). They may appear mainly 
depressed and be incorrectly diagnosed as such 
by psychiatrists; dermatologists may not recog-
nize the distress associated with an apparent fu-
tile preoccupation. However, BDD is a potentially 
debilitating psychiatric illness which needs to be 
identified as it may lead to destructive or life- 
threatening behaviors. 
 Unlike normal concerns about one’s appear-
ance, this condition is associated with significant 
distress and impairment in social and occupational 
life. Close attention should be paid to small clues, 
such as excessive concern over a nonapparent or 
minor defect, amount of time spent checking or 
camouflaging area, skin picking, difficulty in school 
or at work, going from one dermatologist or sur-
geon to another, and being dissatisfied with previ-
ous treatments (14). Self-reporting questionnaires 
can be a guide. Referral to psychiatrists may not 
be a welcomed idea by patients, but focusing on 
the need to address and treat associated behav-
iors may be better understood. Other major pri-
mary psychiatric disorders such as early stages 
of schizophrenia, personality and eating disorders 
may include symptoms of BDD and need to be ex-
cluded. 
 PROGNOSIS
 The onset is usually gradual in adolescence 
and young adulthood (1,25,30). Untreated, it tends 
to be chronic and is a potentially debilitating psy-
chiatric illness which may lead to social withdrawal 
and professional failure, as well as depression and 
suicide in severe cases. 
 TREATMENT
 BDD is a recognizable and treatable disorder 
(30). The need for physicians to identify its symp-
toms and help patients understand the need of 
psychiatric help cannot be overly emphasized. It 
is important to avoid the cycle of multiple surger-
ies requested by some patients to improve their 
imagined flaw, as the outcome is usually poor 
and may lead to exacerbation of symptoms, an-
ger and lawsuits. SSRIs and individual and group 
CBT have been shown to be most effective and 
should be used as a first line therapy (29-31). An-
tipsychotics are ineffective when used alone, but 
may be useful when added in refractory delusional 
cases. Psychotherapy and other medications do 
not help. SSRIs such as clomipramine, fluoxetine, 
fluvoxamine, sertraline and paroxetine have been 
found to be safe and effective for both delusional 
and nondelusional cases, and improve function-
ing and quality of life (32-34). Fluoxetine and clo-
mipramine also have antidepressant activity and 
may be indicated in patients with associated de-
pression, although higher doses are needed and 
response is delayed compared to patients with de-
pression alone. BDD is a chronic disorder which 
should be followed over several years. Treatment 
should not be discontinued abruptly, as there is a 
high rate of relapse. 
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